Epidermal growth factor (EGF) is a crucial factor in mammary gland development [16] and EGFR-targeted therapy provides some promising effects in patients with triple-negative (estrogen receptor-, progesterone receptor-, and erb-b2 receptor tyrosine kinase 2-negative) breast cancer [17]. This evidence concerns the gene ESR1 and breast carcinoma.